Wall Street brokerages expect Endologix Inc (NASDAQ:ELGX) to report earnings of ($0.20) per share for the current quarter, Zacks reports. Four analysts have issued estimates for Endologix’s earnings, with the highest EPS estimate coming in at ($0.17) and the lowest estimate coming in at ($0.24). Endologix reported earnings of ($0.18) per share in the same quarter last year, which indicates a negative year over year growth rate of 11.1%. The company is expected to announce its next quarterly earnings report after the market closes on Wednesday, May 2nd.
According to Zacks, analysts expect that Endologix will report full year earnings of ($0.73) per share for the current fiscal year, with EPS estimates ranging from ($0.92) to ($0.58). For the next year, analysts forecast that the company will post earnings of ($0.60) per share, with EPS estimates ranging from ($0.71) to ($0.50). Zacks’ EPS calculations are a mean average based on a survey of research analysts that cover Endologix.
Endologix (NASDAQ:ELGX) last released its quarterly earnings data on Wednesday, February 21st. The medical instruments supplier reported ($0.08) EPS for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.13. Endologix had a negative return on equity of 44.91% and a negative net margin of 36.65%. The firm had revenue of $44.00 million for the quarter, compared to the consensus estimate of $44.91 million. During the same quarter in the prior year, the company posted ($0.30) earnings per share. The firm’s revenue was down 7.3% on a year-over-year basis.
A number of research firms recently commented on ELGX. Piper Jaffray restated an “overweight” rating on shares of Endologix in a report on Tuesday, December 12th. JPMorgan Chase downgraded Endologix from a “neutral” rating to an “underweight” rating in a report on Tuesday, January 2nd. ValuEngine downgraded Endologix from a “sell” rating to a “strong sell” rating in a report on Sunday, December 31st. BidaskClub downgraded Endologix from a “buy” rating to a “hold” rating in a report on Friday, December 15th. Finally, Oppenheimer set a $5.00 price target on Endologix and gave the company a “hold” rating in a report on Thursday, February 22nd. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and one has issued a buy rating to the stock. Endologix presently has a consensus rating of “Hold” and a consensus price target of $5.41.
Hedge funds have recently made changes to their positions in the business. JPMorgan Chase & Co. grew its holdings in Endologix by 211.2% during the third quarter. JPMorgan Chase & Co. now owns 109,380 shares of the medical instruments supplier’s stock valued at $488,000 after purchasing an additional 74,227 shares during the last quarter. Senzar Asset Management LLC grew its holdings in Endologix by 143.6% during the fourth quarter. Senzar Asset Management LLC now owns 2,196,225 shares of the medical instruments supplier’s stock valued at $11,750,000 after purchasing an additional 1,294,684 shares during the last quarter. Millrace Asset Group Inc. acquired a new position in Endologix during the fourth quarter valued at approximately $669,000. Prosight Management LP acquired a new position in Endologix during the fourth quarter valued at approximately $3,509,000. Finally, ArrowMark Colorado Holdings LLC grew its holdings in Endologix by 11.8% during the fourth quarter. ArrowMark Colorado Holdings LLC now owns 9,890,106 shares of the medical instruments supplier’s stock valued at $52,912,000 after purchasing an additional 1,043,986 shares during the last quarter.
NASDAQ:ELGX traded down $0.04 during mid-day trading on Friday, reaching $4.31. The stock had a trading volume of 39,836 shares, compared to its average volume of 652,999. Endologix has a fifty-two week low of $3.75 and a fifty-two week high of $7.66. The company has a market capitalization of $350.81, a P/E ratio of -8.98 and a beta of 0.32. The company has a debt-to-equity ratio of 2.77, a quick ratio of 1.62 and a current ratio of 2.36.
TRADEMARK VIOLATION WARNING: “Endologix Inc (ELGX) Expected to Post Earnings of -$0.20 Per Share” was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this article on another website, it was stolen and republished in violation of US and international trademark & copyright legislation. The correct version of this article can be read at https://www.dispatchtribunal.com/2018/04/06/endologix-inc-elgx-expected-to-post-earnings-of-0-20-per-share.html.
Endologix Company Profile
Endologix, Inc develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. It offers minimally-invasive endovascular repair (EVAR) products, including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the ovation abdominal stent graft system.
Get a free copy of the Zacks research report on Endologix (ELGX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Endologix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix and related companies with MarketBeat.com's FREE daily email newsletter.